Figure 3.
Figure 3. (A) Overall survival of patients with nodal peripheral T-cell lymphoma, unspecified (PTCL/U). (B) Prognostic index includes age, performance status, LDH, and Ki67 (>80%): group I (0,1 risk factors), median survival 37 months; group II (2 factors), median survival 23 months; group III (3,4 factors), median survival 6 months. / ( Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472–2479. Reprinted with permission from the American Society of Clinical Oncology).

(A) Overall survival of patients with nodal peripheral T-cell lymphoma, unspecified (PTCL/U). (B) Prognostic index includes age, performance status, LDH, and Ki67 (>80%): group I (0,1 risk factors), median survival 37 months; group II (2 factors), median survival 23 months; group III (3,4 factors), median survival 6 months

(

Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472–2479.
Reprinted with permission from the American Society of Clinical Oncology).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal